APA (7th ed.) Citation

EP, H., LG, B., SM, M., W, C., PE, S., MY, M., . . . KA, F. (2025). The clinical and economic impact of genotypic resistance testing for people diagnosed with persistent virological non-suppression on tenofovir-lamivudine-dolutegravir in South Africa: A modelling study. The lancet. HIV, 12(9), e627. https://doi.org/10.1016/S2352-3018(25)00164-X

Chicago Style (17th ed.) Citation

EP, Hyle, et al. "The Clinical and Economic Impact of Genotypic Resistance Testing for People Diagnosed with Persistent Virological Non-suppression on Tenofovir-lamivudine-dolutegravir in South Africa: A Modelling Study." The Lancet. HIV 12, no. 9 (2025): e627. https://doi.org/10.1016/S2352-3018(25)00164-X.

MLA (9th ed.) Citation

EP, Hyle, et al. "The Clinical and Economic Impact of Genotypic Resistance Testing for People Diagnosed with Persistent Virological Non-suppression on Tenofovir-lamivudine-dolutegravir in South Africa: A Modelling Study." The Lancet. HIV, vol. 12, no. 9, 2025, p. e627, https://doi.org/10.1016/S2352-3018(25)00164-X.